Research and Development: Comparing Key Metrics for Zoetis Inc. and Travere Therapeutics, Inc.

R&D Spending: Zoetis vs. Travere - A Decade of Innovation

__timestampTravere Therapeutics, Inc.Zoetis Inc.
Wednesday, January 1, 201447795223396000000
Thursday, January 1, 201550426000364000000
Friday, January 1, 201670853000376000000
Sunday, January 1, 201778168000382000000
Monday, January 1, 2018123757000432000000
Tuesday, January 1, 2019140963000457000000
Wednesday, January 1, 2020131773000463000000
Friday, January 1, 2021210328000508000000
Saturday, January 1, 2022235780000539000000
Sunday, January 1, 2023244990000614000000
Monday, January 1, 2024686000000
Loading chart...

Unveiling the hidden dimensions of data

A Decade of Innovation: R&D Spending in Biopharmaceuticals

In the ever-evolving landscape of biopharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Zoetis Inc. and Travere Therapeutics, Inc. have demonstrated contrasting yet compelling R&D investment strategies.

Zoetis Inc.: A Steady Climb

Zoetis Inc., a leader in animal health, has consistently increased its R&D spending, culminating in a 55% rise from 2014 to 2023. This steady growth underscores Zoetis's commitment to pioneering veterinary solutions.

Travere Therapeutics, Inc.: A Rapid Surge

Conversely, Travere Therapeutics, Inc. has seen a dramatic 412% increase in R&D expenses over the same period. This surge reflects Travere's aggressive pursuit of novel therapies for rare diseases.

Both companies exemplify the critical role of R&D in driving biopharmaceutical advancements, albeit through distinct approaches.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025